Category Archives: Nano medicine

The new report by Expert Market Research titled, Global Advanced Functional Materials Market Report and Forecast 2021-2026, gives an in-depth analysis of the globaladvanced functional materials market, assessing the market based on its type, end-use, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porters Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2016-2026), along with business strategies and detailed market segmentation, please click on request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the reportsummary@https://bityl.co/CaqF

The key highlights of the report include:

Market Overview (2016-2026)

The growth in the global advanced functional materials market is induced by the medical device technology which is advancing at a rapid pace. With increased focus on imaging techniques, implantable devices, and regeneration technologyin medicine, drug delivery industrial equipment, and biomedical engineering, the adoption of advanced functional materials is increasing rapidly, that aims to augment growth of the market. Advanced functional materials supersede conventional materials by having superior characteristics such as durability, toughness, durability, and elasticity. The advanced functional material industry for low carbon emissions applications is anticipated to be driven by rising lightweight vehicles demandcombined with improved fuel efficiency.

Explore the full report with the table ofcontents@https://bityl.co/CaqC

Industry Definition and Major Segments

Usingeffective power and signaltransmission to every object, advanced functional materials serve to minimise total power usage. Thin conductors or interlinks used within advanced functional material-based mini electronics aid in countering signal propagation and power failure concerns associated with large PCBs and thick interconnects.

Based on its types, the market is divided into:

Based on end-use, the market is divided into:

On the basis of region, the market is divided into:

Market Trends

In the years ahead, the manufacturing of lighter weight, handy, and adaptable substrate technological tools will boost adoption ofadvanced functional materials. One of the crucial industry trends in the advanced functional materials marketis the strong market for microelectronics andminiaturisation. The healthcare industry has a huge demand for advanced functional materials. In the industry, nanomaterials are the dominant type of material. The use of nano materials in the nanotechnological sector of the healthcare industry is consistently expanding. Nanomedicine is the use of nanotechnology to diagnose, monitor, deliver drugs, treat, and regulate biological systems. Although, an absence of expansion plans and technological innovation is anticipated to stymie the industrys growth over the forecast period.

Key Market Players

The major players in the market are Morgan Advanced Materials plc, KYOCERA Corporation, Hexcel Corporation, Nanophase Technologies Corporation, KURARAY CO., LTD, Murata Manufacturing Co., Ltd., and Henkel AG & Co. KGaA (OTCMKTS: HENKY), among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: Claight CorporationContact Person: Louis Wane, Corporate Sales Specialist U.S.A.Email:sales@expertmarketresearch.comToll Free Number:+1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USAWebsite:https://www.expertmarketresearch.com

Read More:

Electric Cargo Bikes Market:https://www.digitaljournal.com/pr/global-electric-cargo-bikes-market-to-be-driven-by-the-growing-environmental-consciousness-around-the-globe-in-the-forecast-period-of-2021-2026

Dehydrated Food Market:https://www.digitaljournal.com/pr/global-dehydrated-food-market-to-be-driven-by-increasing-consumer-demand-for-packaged-and-processed-food-products-in-the-forecast-period-of-2021-2026

Human Insulin Market:https://www.digitaljournal.com/pr/global-human-insulin-market-to-be-driven-by-rising-health-awareness-among-increasing-diabetic-population-across-the-globe-in-the-forecast-period-of-2021-2026

Power Over Ethernet Lighting Market:https://www.digitaljournal.com/pr/power-over-ethernet-lighting-market-to-be-driven-by-demand-for-advanced-technology-coupled-with-its-extensive-range-of-application-in-different-sectors-across-the-globe-in-the-forecast-period-of-2021

Marine Engines Market:https://www.digitaljournal.com/pr/marine-engines-market-to-be-driven-by-the-rapidly-growing-shipping-industry-in-the-forecast-period-of-2021-2026

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Continued here:
Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women...

WHO. Global Tuberculosis Report. 2020. (2020).

Mabhula, A. & Singh, V. Drug-resistance in Mycobacterium tuberculosis: where we stand. MedChemComm 10, 13421360 (2019).

ADS CAS Article Google Scholar

Saifullah, B., Hussein, M. Z. B. & Al Ali, S. H. H. Controlled-release approaches towards the chemotherapy of tuberculosis. Int. J. Nanomed. 7, 5451 (2012).

CAS Article Google Scholar

Tafazoli, S., Mashregi, M. & OBrien, P. J. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol. Appl. Pharmacol. 229, 94101 (2008).

CAS Article Google Scholar

Saifullah, B. et al. Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide. Int. J. Nanomed. 9, 4749 (2014).

Google Scholar

Erwin, E. R., Addison, A. P., John, S. F., Olaleye, O. A. & Rosell, R. C. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinburgh, Scotland) 116s, S66S70. https://doi.org/10.1016/j.tube.2019.04.012 (2019).

CAS Article Google Scholar

Schaberg, T., Rebhan, K. & Lode, H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 9, 20262030 (1996).

CAS Article Google Scholar

Zhang, Y., Heym, B., Allen, B., Young, D. & Cole, S. The catalase: Peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591593 (1992).

ADS CAS Article Google Scholar

Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227230 (1994).

ADS CAS Article Google Scholar

Musser, J. M. et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance. J. Infect. Dis. 173, 196202 (1996).

CAS Article Google Scholar

Basso, L. A., Zheng, R., Musser, J. M., Jacobs, W. R. Jr. & Blanchard, J. S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178, 769775. https://doi.org/10.1086/515362%JTheJournalofInfectiousDiseases (1998).

CAS Article PubMed Google Scholar

Park, Y. K. et al. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea. J. Microbiol. Methods 63, 165172 (2005).

CAS Article Google Scholar

Luo, T. et al. Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob. Agents Chemother. 54, 10751081 (2010).

CAS Article Google Scholar

Haas, W. H. et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41, 16011603 (1997).

CAS Article Google Scholar

Doustdar, F., Khosravi, A. D., Farnia, P., Masjedi, M. R. & Velayati, A. A. Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. Microb. Drug Resist. 14, 273279 (2008).

CAS Article Google Scholar

Khosravi, A. D., Goodarzi, H. & Alavi, S. M. Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allele-specific polymerase chain reaction. Braz. J. Infect. Dis. 16, 5762 (2012).

CAS PubMed Google Scholar

Munoz-Bellido, J. L., Munoz-Criado, S. & Garca-Rodrguez, J. A. Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14, 177180 (2000).

CAS Article Google Scholar

de Sousa, A. K. et al. New roles of fluoxetine in pharmacology: Antibacterial effect and modulation of antibiotic activity. Microb. Pathog. 123, 368371 (2018).

Article Google Scholar

Sheikhpour, M. The current recommended drugs and strategies for the treatment of coronavirus disease (COVID-19). Ther. Clin. Risk Manag. 16, 933 (2020).

CAS Article Google Scholar

Peng, L., Gu, L., Li, B. & Hertz, L. Fluoxetine and all other SSRIs are 5-HT2B agonists-importance for their therapeutic effects. Curr. Neuropharmacol. 12, 365379 (2014).

CAS Article Google Scholar

Ni, Y. G. & Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. 94, 20362040 (1997).

ADS CAS Article Google Scholar

Stanley, S. A. et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).

Article Google Scholar

Sheikhpour, M., Golbabaie, A. & Kasaeian, A. Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment. Mater. Sci. Eng., C 76, 12891304 (2017).

CAS Article Google Scholar

Yang, W., Thordarson, P., Gooding, J. J., Ringer, S. P. & Braet, F. Carbon nanotubes for biological and biomedical applications. Nanotechnology 18, 412001 (2007).

Article Google Scholar

Kamazani, F. M., Siadat, S. D., Pornour, M. & Sheikhpour, M. A success targeted nano delivery to lung cancer cells with multi-walled carbon nanotubes conjugated to bromocriptine. Sci. Rep. 11, 115 (2021).

Article Google Scholar

Mocan, T. et al. Carbon nanotubes as anti-bacterial agents. Cell. Mol. Life Sci. 74, 34673479 (2017).

CAS Article Google Scholar

Sheikhpour, M., Arabi, M., Kasaeian, A., Rabei, A. R. & Taherian, Z. Role of nanofluids in drug delivery and biomedical technology: Methods and applications. Nanotechnol. Sci. Appl. 13, 47 (2020).

CAS Article Google Scholar

da Silva, P. et al. Nanotechnology-based drug delivery systems for treatment of tuberculosis: A review. J. Biomed. Nanotechnol. 12(2), 241260 (2016).

Article Google Scholar

Zomorodbakhsh, S., Abbasian, Y., Naghinejad, M. & Sheikhpour, M. The effects study of isoniazid conjugated multi-wall carbon nanotubes nanofluid on Mycobacterium tuberculosis. Int. J. Nanomed. 15, 5901 (2020).

CAS Article Google Scholar

Sheikhpour, M. et al. The applications of carbon nanotubes in the diagnosis and treatment of lung cancer: A critical review. Int. J. Nanomed. 15, 7063 (2020).

CAS Article Google Scholar

Jain, S. N. et al. Antibiotic synergy test: Checkerboard method on multidrug resistant Pseudomonas aeruginosa. Int. Res. J. Pharm. 2, 196198 (2011).

Google Scholar

Lorian, V. Antibiotics in Laboratory Medicine (Lippincott Williams & Wilkins, 2005).

Google Scholar

Munoz-Bellido, J., Munoz-Criado, S. & Garca-Rodrguez, J. Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. Int. J. Antimicrob. Agents 14, 177180 (2000).

CAS Article Google Scholar

Ni, Y. & Miledi, R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. 94, 20362040 (1997).

ADS CAS Article Google Scholar

Rawat, R., Whitty, A. & Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. 100, 1388113886 (2003).

ADS CAS Article Google Scholar

Vgeli, B. et al. InhA, the enoyl-thioester reductase from Mycobacterium tuberculosis forms a covalent adduct during catalysis. J. Biol. Chem. 293, 1720017207 (2018).

Article Google Scholar

Kumar, M. M. K., Madhavi, K., Mohan, T., Nagasree, K. P. & Sangeeta, G. Novel synthetic analogues of Fluoxetine as potent and selective anti-TB agents. J. Appl. Pharm. Sci. 8, 107115 (2018).

CAS Google Scholar

Schrlau, M. G., Falls, E. M., Ziober, B. L. & Bau, H. H. Carbon nanopipettes for cell probes and intracellular injection. Nanotechnology 19, 015101 (2007).

ADS Article Google Scholar

Ladel, C. H. et al. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 65, 48434849 (1997).

CAS Article Google Scholar

Sheikhpour, M., Barani, L. & Kasaeian, A. Biomimetics in drug delivery systems: A critical review. J. Control. Release 253, 97109 (2017).

CAS Article Google Scholar

Ma, W. et al. Efficacy of dual-targeting combined anti-tuberculosis drug delivery system in the treatment of tuberculous meningitis. J. Biomed. Nanotechnol. 17(10), 20342042 (2021).

CAS Article Google Scholar

Mazlan, M. K. N. et al. Antituberculosis targeted drug delivery as a potential future treatment approach. Antibiotics 10(8), 908 (2021).

CAS Article Google Scholar

Mohammadi, M., Arabi, L. & Alibolandi, M. Doxorubicin-loaded composite nanogels for cancer treatment. J. Control. Release 328, 171191 (2020).

CAS Article Google Scholar

Continue reading here:
An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com

By Srinivas Iyengar

One of the most awaited technologies on the verge of moving out of laboratories and set to enter commercial production is nanotechnology. There is so much buzz about nanotechnology that industries, from cosmetics, healthcare, and automobile to aerospace, expect big disruptions due to nanotech. In the race for nano supremacy, I see healthcare as the most exciting space with a variety of use cases that can have a profound impact on humankind. In fact, nanotechnology is the most radical and wide-reaching emerging technology, and healthcare is its most urgent application.

Before we delve deeper into the application of nanotechnology in healthcare, let us take a closer look at nanotechnology, its use cases, and its market share. This will give us a clearer perspective and some critical insights into this emerging technology.

Lets understand what a nanometer is all about. To give you a better perspective, A virus, on average, is 40- 100 nanometers in size! Isnt it amazing that we are now dealing with things 1/100th the size of a virus? And these subatomic particles are making big waves today! We are building nanorobots, nanotubes, nanodots, nanowires, and nanosheets that could be used for innovative and pathbreaking medical applications from diagnosis of disease and drug delivery to the disease-affected areas of the human body with great precision, something that hasnt been actively pursued until now.

The space where nanotechnology meets healthcare is called nanomedicine. Industry experts estimate the nanomedicine market share to grow up to $260Bn in 2025 from $141Bn in 2020.

While nanostructures occur naturally in soil, dust, oceans, plants, and animals, scientists today are building nano materials with newly manipulated attributes or engineered properties. This holds massive potential and opens new doors in drug delivery systems, body scans, gene therapy, identifying cancer cells, and health monitoring.

The lexicon of Nanotechnology Before outlining the possible use cases of nanotechnology in healthcare, it would serve us well to be acquainted with the basic verbiage of nanotechnology

Nanometer (m): A nanometer is a unit of measurement which is 1 billionth of a meter. The smallest things around us are measured in nanometers. To illustrate, a DNA molecule is about 2.5 m wide compared to a red blood cell which is about 7 m.

Nanoparticles (Nanodots/Quantum dots): These are small particles that range anywhere between 1 to 100 Nm. We all know well that the smaller the material, the surface area to volume ratio increases. This ensures that nanoparticles have distinct optical, physical, and chemical properties and produce quantum effects.

Nanotubes: These are tubes with atom-thick walls and a tube-like structure mainly made of carbon materials. Nanotubes are a few nanometers wide, and their length can be up to a few millimeters. What makes them more attractive in the healthcare arena is that they are non-toxic and, therefore, safe to use.

Nanorobotics: Nanorobotics is the process of building robots at the nanoscale and such robots are called nanobots. They are typically nanoelectromechanical systems that can be programmed to carry out specific tasks.

The most promising use-cases of Nanotechnology in HealthcareIndustry experts believe that nanotechnology will play a pivotal role in shaping the future of healthcare. Lets take a look at some of its most compelling use cases that are already show promising results

Targeted Drug Delivery System: In todays conventional drug delivery mechanism, did you know that when you take a medicine for a headache, it possibly goes through your entire body, including the head, to give you relief? This also means that the drug delivery mechanism is inefficient, slow, requires more drug consumption than needed, and may impact non-targeted organs. Nanotechnology can carry drugs to specific cells and release them when it reaches the targeted organ or area. This can be highly instrumental, for instance, in curtailing the side effects of chemotherapy.

Diagnosis: A biomarker, in general, is a measurement, substance, or chemical in the body which indicates a disease or a condition. It is seen that nanotechnology can bridge the gap between measurable biomarkers representing the physiology of a biological process and clinical outcomes. Nanoparticles injected into humans can detect these biomarkers with extremely high efficacy as compared to scanning the human body from the outside, thereby reducing the chances of drug failure/rejection.

Medical Imaging: Nanoparticles/Quantum dots are so small that their surface area to volume ratio is relatively high, thus producing excellent contrast and fluoresce. In generic terms, a nanoparticle is more like a glow-in-the-dark thing, and its ability to reflect light will help us in biological labeling at the molecular level. Nanoparticles in medical devices and drug therapy can give us much better diagnosis results and treatments with a higher success rate.

Wound Treatment: One of the major pain points of wound healing is contamination with microorganisms. Silver nanoparticles have antibacterial and anti-inflammatory properties that provide better wound healing efficacy with less bacterial resistance. They can be used as scaffolds for skin regeneration. Nanofibrous materials can also be used as delivery systems for drugs, proteins, growth factors, and other molecules. This will help us in targeted drug delivery with minimal and effective drug usage.

Needless to say, there exists great scope for advancements in nanotechnology that hold the potential to revolutionize and reinvent healthcare systems despite existing hurdles. Nanomedicine, nano pharmacology, nanoimaging, and targeted drug delivery systems will make the diagnosis and prevention of diseases, and care delivery more efficient and patient-centric.

By Srinivas Iyengar, VP & Head of Healthcare & Life Sciences, Happiest Minds Technologies.

(DISCLAIMER: The views expressed are solely of the author and ETHealthworld does not necessarily subscribe to it. ETHealthworld.com shall not be responsible for any damage caused to any person / organisation directly or indirectly)

Originally posted here:
Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld

Being diagnosed with any illness is unnerving, but imagine you are one of only 30 people in the world to suffer from the illness or at least a particular form of it. Now, imagine that that disease is 100% fatal. Thats the reality faced by the Amyotrophic lateral sclerosis (ALS) patients being treated as part of a new initiative between Columbia University and non-profit biotech company n-Lorem Foundation.

These diseases or disease mutations have been dubbed nano-rare by San Diego-based n-Lorem, whose mission is to find effective treatments for these uniquely afflicted individuals and others like them.

There are few commercial incentives for pharmaceutical or biotech organizations to pursue the discovery and development of individualized treatments, n-Lorem Chief Development Officer Sarah Glass, Ph.D. told BioSpace. The 2021 FDA guidance documents for individualized antisense oligonucleotides have enabled this non-commercial route for n-Lorems non-profit model, which is driven entirely by the desire to help patients by embedding the same level of quality that is required for standard commercial drugs."

In recent years, researchers have come to the consensus that ALS is a heterogeneous disease. This is evidenced by patient subsets that have responded favorably to drugs like Radicava, which was approved in 2017 and BrainStorm Cell Therapeutics NurOwn, which is still fighting an uphill battle for approval.

Glass said that providing a blanket definition of ALS almost does [patients] a disservice given the many unique individuals within this patient group. Individuals with ALS that carry a nano-rare mutation are often one of only a few - or perhaps the only one - that are known to have this mutation worldwide."

Lisa Stockman Mauriellofaced a similar situation. Suffering from a particularly lethal A5V mutation within SOD1-ALS, Stockman Mauriello captured the nations attention and reinvigorated the ALS community in its fight for expanded access to investigational therapies.

Stockman Mauriello was fighting for access to the experimental therapy tofersen, which was being developed by Biogen and Ionis Pharmaceuticals. Tofersen is an antisense oligonucleotide (ASO) that targets a mutation in the superoxide dismutase 1 (SOD1) gene believed to be responsible for the genetic driver in SOD1-ALS, the second most common form of inherited, or familial ALS. This category is rare itself, accounting for just 2% of all ALS cases. Ultimately, tofersen failed to achieve its endpoint in Phase III, and although Stockman Mauriello eventually did receive access to the drug, she succumbed to her disease in August 2021.

The n-Lorem-Columbia project, Silence ALS, is funded by medical nonprofit Target ALS and focuses on developing personalized experimental ASO medicines for nano-rare ALS patients. Currently, eight patients have been accepted into the program. These patients are afflicted with nano-rare mutations in either TDP-43 or CHCHD10.

In the first case, the TDP-43 protein is incorrectly ejected from the cells nucleus, preventing it from performing essential functions such as ensuring that mRNA is produced correctly, which can produce chaotic effects in affected nerve cells. Mutations in the CHCHD10 gene were identified as a genetic cause of ALS in 2014. While the process is not yet well understood, some studies suggest the mutations lead to impaired functioning of mitochondria, the cellular structures that provide the energy necessary for survival. Then, there are separate mutations within both.

These are genes that are well known in the ALS community. They are very well characterized and have been extensively studied by the research community. Unique mutations may occur in any gene and n-Lorem is learning more and more about the types of mutations and genes that ASOs can target, Glass said. The Silence ALS partnership will enable iterative learning to help the broader population over time.

She explained how ASOs can address these mutations.

These are short segments of single-stranded genetic material that bind in a sequence-specific manner to RNA to alter the behavior and performance of that target RNA. ASOs can target a specific mutation as well as different variants that uniquely differentiate that patient from others. Glass added that for some patients, it may be necessary to differentiate the disease-causing allele from the normal allele.

ALS is a progressive, neurodegenerative disease. From the time of diagnosis, a patient can expect to live between 2-5 years. During that time, they will become increasingly paralyzed, losing the ability to walk, talk, eat, swallow and finally, breathe. Glass shared that this is a big part of the reason n-Lorem teamed up with Neil Shneider at Columbia on this initiative.

The clock is ticking. One of the biggest goals of the partnership is really to introduce efficiencies such as proactive sequencing, acquiring patient cells and other elements that are required to be able to accelerate our ability to develop an individualized therapy, she said.

One of these efficiencies is ensuring that patients are characterized at an early stage in their disease prognosis. Then, the ultimate end goal would be to eventually get to the place where we can try to preempt, almost pre-symptomatically be able to develop these ASOs when the natural history of a particular mutation is known.

Glass shared that there are thousands and thousands of nano-rare diseases and patients with nano-rare mutations. Besides ALS, n-Lorem is primarily focused on helping patients with other neurodegenerative diseases as well as those with severe neurodevelopmental, ophthalmologic and kidney diseases. The foundations neurological concentration owes to it being where patients are mostly diagnosed from a genetics perspective, she explained.

Genetic testing and genome sequencing has become much more common in the rare neurological disease space and many neurologists are becoming increasingly aware of the potential of individualized therapies. This is reflected in the fact that many patients for whom n-Lorem is discovering an ASO are affected primarily by neurological manifestations. Glass said. She clarified that n-Lorem is also already developing ASOs for patients with diseases in other organ systems as well and will continue to expand the breadth of the patients it can help.

Its been understood for a while now that personalized medicine is the way of the therapeutic future, and initiatives like this one reflect that sentiment.

As genetic sequencing becomes more common, it has become apparent that more and more pathogenic mutations are nano-rare and will require individualized treatments that are out of scope for commercial organizations, she said.

Glass suggested that partnering is key to leveraging platform approaches and collective abilities to find commonalities [and therefore therapeutic efficiencies] across some of these nano-rare diseases. How can we learn and try to think across different genes, different mutations that have a number of similarities and commonalities? This could ultimately lead to the nano-rare becoming a little less rare.

Glass, who did her Ph.D. in a rare form of cancer, shared that she has always had a passion for genetics and rare diseases. Then in 2020, her own son was diagnosed with a rare disease. Being immersed in drug discovery and development and now having a child with an N-of-1 mutation as well, she wondered how one could go about successfully developing a therapy for individual patients.

At the time, I reached out to Dr. Stan Crooke [founder and CEO of n-Lorem], the pioneer of RNA-targeted drugs, she said. I immediately learned a lot and was drawn to the mission. My joining n-Lorem was an organic evolution of my career and represented the true intersection of my personal and professional passions. Since joining Crooke, Glass has been working feverishly to stand up an infrastructure to enable many more patients to be helped.

Follow this link:
New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace

DUBLIN, May 09, 2022--(BUSINESS WIRE)--The "Nanotechnology in Medical Applications: The Global Market" report has been added to ResearchAndMarkets.com's offering.

Nano-enabled medical products began emerging on the market over a decade ago, and some have evolved as the best-sellers in their therapeutic categories. The leading areas in which nanomedical products have made an impact are CNS diseases, cancer, cardiovascular disease, and infection control.

Moreover, the availability of technologically advanced products and significant investments in nanotechnology-based research in drug discovery studies and cancer therapeutics will also drive the North American market during the forecast period. The Asia-Pacific region's high growth rate will be due to the drive to address unmet healthcare needs, high prevalence of cancer, high investments in nanotechnology-based research, and growing R&D funding for cancer drug discovery and personalized medicine opportunities.

The report examines the current and forecast market potential for nanomedicine. It offers a detailed analysis of the market background, technological advancements, competitive environment, drivers and restraints, and market growth trends.

The report includes market projections through 2026, detailing the market share for nanomedicine based on therapeutic areas and geography. By therapeutic area, the nanomedicine market is segmented into anticancer, CNS products, anti-infectives, anti-inflammatories, cardiovascular, and others. By geography, the nanomedicine market has been segmented into Europe, North America, Asia-Pacific (APAC), and the Rest of the Word (ROW).

The Report Includes

An overview of the global markets for nanotechnology used in medical applications

Estimation of the market size, and analyses of the global market trends with data from 2019, 2020, 2021, with projection of CAGR through 2026

A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications

Information on significant products in which the nano dimension has made a significant contribution to product effectiveness

A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine

Identification of key market dynamics, trends, opportunities, and factors influencing the global market and highlights of the market potential for nanotechnology used in medical applications based on type, application, and region

Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies

Company profiles of major players in the market, including Abbott, Abraxis Bioscience, Elan, Orthovita Inc., EyePoint Pharmaceuticals Inc. and Farfield Scientific Ltd

Story continues

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Applications

Drug Delivery

Drugs and Therapy

in Vivo Imaging

in Vitro Diagnostics

Biomaterials

Active Implants

Overview

Medical Nanotechnology: Nanomedicine

Nanotechnology

Nanotechnology Uses

Medical Applications

Environmental Applications

Military Applications

Cosmetics

Nanotechnology Tools

Risks of Nanotechnology

Nanotechnology in the Marketplace

Development of Nanomedical Technologies

Liposomes

Dendrimers

Nanocrystals

Micelles

Fullerenes

Polymeric Nanoparticles

Nanoparticle-Drug Conjugates

Ligand-Targeted Nanoparticles

Ceramic Nanoparticles

Virosome Nanoparticles

Therapeutic Uses of Nanomedicine

Cancer Diagnostics and Therapy

Drug Delivery

Future Trends and Research Possibilities

Non-Invasive Nanodevices

Extracellular Devices

Intracellular Devices

Nanomachines to Control Tissue Healing

Eliminating Viruses

Correcting Chemistry

New Organs and Limbs

Fundamental Nanotechnology Research

Chapter 4 Impact of Covid-19 Pandemic

Chapter 5 Markets for Nanomedicine

Market Drivers

Market Estimates and Forecasts

Global Nanomedicine Market

Main Product Categories

Market Analysis by Clinical Application

Chapter 6 Global Nanomedicine Market Breakdown by Region

Chapter 7 Competitive Landscape

Chapter 8 Company Profiles

Abbott

Abraxis Bioscience

Aphios Corp.

Bioforce Nanosciences Holdings Inc.

C Sixty Inc.

Elan (Alkermes)

Eyepoint Pharmaceuticals Inc.

Farfield Scientific

Kleindiek Nanotechnik GmbH

Liplasome Pharma Aps

Magforce Nanotechnologies

Microfluidics Corp.

Nanobio Corp.

Nanobiotix Sa

Nanocarrier Co. Ltd.

Nanocopoeia, LLC.

Nanologix Inc.

Nanomix Inc.

Nanospectra Biosciences Inc.

Nanostructures Inc.

Orthovita Inc.

Pfizer Inc.

Sanofi S.A.

Starpharma

Tecangroup Ltd.

Transgenex Nanobiotech Inc.

For more information about this report visit https://www.researchandmarkets.com/r/dao9n5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005452/en/

Follow this link:
Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint...

In 2019, Ikea announced it had developed curtains that it claimed could break down common indoor air pollutants. The secret, it said, was the fabrics special coating. What if we could use textiles to clean the air? asked Ikeas product developer, Mauricio Affonso, in a promotional video for the Gunrid curtains.

After explaining that the coating was a photocatalyst (similar to photosynthesis, found in nature), Affonso is shown gazing up at the gauzy curtains while uplifting music plays. Its amazing to work on something that can give people the opportunity to live a healthier life at home.

Puzzled by these claims how could a mineral coating clean the air? Avicenn, a French environmental nonprofit organisation, investigated. Independent laboratory tests of the Gunrid textile reported that samples contained tiny particles of titanium dioxide (TiO2) a substance not normally toxic but which can be possibly carcinogenic if inhaled, and potentially in other forms which supposedly gives self-cleaning properties to things such as paint and windows when exposed to sunlight.

These tiny particles, or nanoparticles, are at the forefront of materials science. Nanoparticles come in all shapes spheres, cubes, fibres or sheets but the crucial thing is their size: they are smaller than 100 nanometres (a human hair is approximately 80,000nm thick).

Many nanoparticles exist in nature. Nano-hairs make a geckos feet sticky, and nano-proteins make a spiders silk strong. But they can be manufactured, and because they are so small, they have special properties that make them attractive across a range of endeavours not just to companies such as Ikea. In medicine, they can transport cancer drugs directly into tumour cells, and nanosilver is used to coat medical breathing tubes and bandages. Nanos could direct pesticides to parts of a plant, or release nutrients from fertilisers in a more controlled manner.

They also have more mundane uses. Synthetic nanos are added to cosmetics and food. Nanosilver is used in textiles, where it is claimed to give antibacterial properties to plasters, gym leggings, yoga mats and period pants.

But scientists such as those at Avicenn are concerned that when these household items get washed, recycled or thrown away, synthetic nanos are released into the environment making their way into the soil and sea in ways that are still not understood. Some scientists believe nanoparticles could pose an even greater threat than microplastics.

Synthetic nano particles of plastic have been found in the ocean and in ice on both poles. Nanoparticles from socks and sunscreen have been found to pollute water, and certain nanos have been shown to negatively affect marine wildlife including fish and crustaceans. As with antibiotics, resistance to antimicrobial nanosilver can develop silver-tolerant soil bacteria have now been found.

Little is known even about where nanoparticles are, let alone their effects on the environment. As they are so tiny, most experiments are conducted in labs, and it can be hard to pin down where they are applied.

The main problem with these substances is that we cannot measure them we know they are there but theyre so tiny theyre difficult to detect, which is why you dont hear as much about them, says Nick Voulvoulis, professor of environmental technology at Imperial College London.

He worries about the uncontrolled use of nanos in consumer products. If nanos are used properly in applications that are useful or beneficial, thats justified, but if they are used anywhere and everywhere because they have certain properties, thats crazy.

Synthetic nanoparticles are not inherently harmful. Like their natural cousins, many are metal-based, but they can be made of any substance. Crucially, unlike chemical compounds, they cannot be dissolved. Their tiny size gives them, paradoxically, an enormous surface area, which makes them behave differently to non-nano versions of the same material. It can make them more mobile, more reactive and potentially more toxic, depending on shape, size, type, how a substance is released into the environment and its concentration.

And released into the environment they are, on a massive scale. According to Avicenn, the release of nanos is most likely during manufacture or disposal, but it can also happen when items are washed which is known to occur with fabrics containing nanosilver. Sewage systems cannot trap them and they end up in the ocean: the OECD says even advanced wastewater-treatment plants cannot deal with nanoparticles.

From a health perspective, inhalation is the most harmful route of exposure to nanos such as TiO2 for factory workers and consumers. Avicenns tests concluded that the average particle size was 4.9nm, and all 300 particles analysed were below the official nano threshold of 100nm.

Ikea insisted its own tests showed the TiO2 particles were properly bound to the fabric and pose no risk to customers, and said it took workers safety extremely seriously. The firm has not referred to them as nanoparticles, and said that once integrated into textile surfaces there was no good standard method to measure the particle size distribution of a material, acknowledging that EU definitions of nanomaterials were under review.

We recognise that the tests and measurements of nano-particles are complex, especially for materials containing particles that tend to form agglomerates, it said.

As for Ikeas curtains shedding TiO2 nanoparticles when washed or discarded, Ikea said it was confident that the treatment is properly bound to the fabric, and therefore we do not see a risk of inhaling the treatment, but acknowledged that as with any textile, parts of the textile can come off during use or washing.

Many nanos do not persist for long in the environment. However, because they are consistently being discharged, levels remain fairly constant. Nanos are pseudo-persistent because they degrade quite quickly but they keep entering the environment, Voulvoulis says.

His main concern is whether nanos become carriers for other compounds, a subject of scientific debate. In 2009, Spanish scientists suggested nanos could bind to and transport toxic pollutants, and possibly be toxic themselves by generating reactive free radicals. If other toxic pollutants latch on to nanos surfaces, they argued, marine plants and animals could absorb them more easily.

Other scientists suggest the opposite: that organic matter in sewage coat nanoparticles, rendering them less active. And others fear nanos could trigger toxic cocktail effects making them more harmful in combination than individual substances would be separately.

So far, synthetic nanomaterials are relatively dispersed in the sea, and unlikely to significantly affect marine animals, says Dr Tobias Lammel of Gothenburg University, who has studied copper nanos. But he warns: Its possible that the concentration of some manufactured nanomaterials in the marine environment will increase It is important to keep an eye on this.

Given the huge question marks, Avicenn wants more stringent regulations on nanos, and more caution in product design. Companies are eager to sell innovative and fancy products, but they must thoroughly assess their benefits-risks balance at each step of the life-cycle of the products, says Mathilde Detcheverry, Avicenns policy manager.

From August, the EU will ban use of TiO2 nanos in food (where it is called E171) and the European Commission recently announced that 12 nanomaterials would soon be prohibited in cosmetics.

Detcheverry says: As scientific knowledge about the environmental and health impacts of engineered nanos such as silver and titanium dioxide advances, we need to make sure nanos are only allowed for specific and essential uses in order to minimise any adverse effects at the source and [ensure they are] not released uncontrollably.

Two years after the release of Ikeas Gunrid curtains, Avicenn tried to buy more for further tests, but they had been withdrawn from sale.

Ikea told the Guardian that Gunrid remained safe to use as a traditional curtain but it was withdrawn because the functionality was not as effective as expected. If thats true for example, that despite TiO2 having proven photocatalytic properties and being used in self-cleaning and air-purifying products, its efficacy on curtains could be localised and not powerful then at the very least Ikeas experience suggests nanoparticles benefits may not outweigh the potential and frequently unknown risks, Detcheverry says.

Nanoparticles are often promoted as silver bullets against pollution or bacteria, she says, but we must make sure that the cure is not worse than the disease.

Gunrid was just one product of many thousands that use nanoparticles. As Ikeas Affonso says in the video: Whats so great about Gunrid is that this technology could be applied to any textile.

This article was amended on 26 April 2022 to correct the spelling of Gothenburg.

More here:
Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian

Nanomedicine Market Overview

The nanomedicine market has been predicted to grow at a noticeable pace in the forthcoming years. The growth opportunities in the global market are attributed to the emerging innovative technologies for the delivery of the drug. In addition to this, advantages related to nanomedicine in different healthcare applications along with growth in the requirement for cost-effective and safe therapies. Thus, based on these factors, the global market has been predicted to drive growth opportunities in the global market during the forecast period.

Get Exclusive PDF Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7961

Nanomedicine is a branch of medicine that commonly applies the knowledge of nanotechnology to prevent and treat diseases. Further, nanomedicine involves the use of nanoscale materials, for instance, nanorobots and biocompatible nanoparticles to diagnose, deliver, sense, or for actuation purposes in the living organism.

Nanomedicine Market Key Drivers

Rising R & D activities related to nanorobots and noteworthy investments in the clinical trials by private as well as government sectors are projected to contribute to the growth impetuses in the nanomedicine market in the near future.

Nanomaterials generally possess novel physicochemical properties that vary from the traditional bulk chemical equivalents because of their smaller size. Further, these properties increase the set of opportunities in the development of drugs. These properties of nanoformulation can lead to alteration of pharmacokinetics, for instance, metabolism, elimination, distribution, and absorption. These properties have the potential to cross biological barriers and toxic properties. They are persistent in the human body and environment. Thus, on the basis of these advanced features, the nanomedicine market has been estimated to expand at a noteworthy speed in the following years.

On the flip side, the risk associated with nanomedicines, especially environmental impact and long approval process is estimated to restrict the growth prospects in the global market. Growth of the healthcare facilities and increasing out-licensing of the nano drugs are estimated to provide novel growth avenues in the global market in the following years.

Buy This Report @ https://www.tmrresearch.com/checkout?rep_id=7961&ltype=S

Nanomedicine Market Recent Developments and Key Players

The nanomedicine market is fragmented in nature. The market is further characterized by the presence of certain regional and international players. In addition to this, the market players are focusing on various strategies for the achievement of their desired profits, the development of brand awareness, and penetration in the developing markets. Furthermore, these market players concentrate on the enhancement of their services in order to gain a large consumer base. Novel product launches, agreements or partnerships, expansion of company networks, and mergers and acquisitions are certain factors that are estimated to drive the growth opportunities in the global market during the forecast period.

Some of the key players in the nanomedicine market are:

Nanomedicine Market Regional Assessment

The nanomedicine market has been divided into four major regional areas that include North America, Europe, Asia Pacific, and LAMEA. North America is predicted to hold a noteworthy share in the global market because of the increasing number of lethal diseases. In addition to this, availability of the advanced healthcare facilities and surging demand for nanomedicines are also estimated to create sales avenues in the regional market in the near future. In addition to this, the availability of trained healthcare professionals, the presence of larger market players, increased investments that are made by government bodies in the healthcare system, and the growing number of R & D activities are some other pivotal factors that are likely to stimulate the expansion opportunities in the nanomedicine market in the following years.

To know more about the table of contents, you can click @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7961

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original post:
Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt...

The NCI Cancer Nanotechnology Plan is a strategic document used by the NCI to guide the nanotechnology and onocoolgy fields in the future. The 2015 version is downloadable from this page.

Credit: National Cancer Institute

Currently, scientists are limited in their ability to turn promising molecular discoveries into cancer patient benefits. Nanotechnology the science and engineering of controlling matter, at the molecular scale, to create devices with novel chemical, physical and/or biological properties can provide technical control and tools to enable the development of new diagnostics, therapeutics, and preventions that keep pace with todays explosion in knowledge.

Nanotechnology has the potential to radically change how we diagnose and treat cancer. Although scientists and engineers have only recently (ca. 1980's) developed the ability to industrialize technologies at this scale, there has been good progress in translating nano-based cancer therapies and diagnostics into the clinic and many more are in development.

Nanotechnology is the application of materials, functionalized structures, devices, or systems at the atomic, molecular, or macromolecular scales. At these length scales, approximately the 1-100 nanometer range as defined by the U.S. National Nanotechnology Initiative (NNI) , unique and specific physical properties of matter exist, which can be readily manipulated for a desired application or effect. Furthermore, nanoscale structure can be used as individual entities or integrated into larger material components, systems, and architectures.

Nanoscale devices are one hundred to ten thousand times smaller than human cells. The depiction displays this scale in size.

Credit: National Cancer Institute

This emerging field involves scientists from many different disciplines, including physicists, chemists, engineers, information technologists, and material scientists, as well as biologists. Nanotechnology is being applied to almost every field imaginable, including electronics, magnetics, optics, information technology, materials development and biomedicine. Nanotechnology-based structures and devices are already enabling a large number of novel applications in various fields including medicine.

Nanotechnology offers many possible benefits to cancer therapy, detection and diagnosis. The benefits begin by way of the fundamental properties of nanotechnology and the biological challenges of which it can help to overcome.

In cancer, half the battle is won by its earlier detection and enhanced diagnosis. Furthmore, tools to enable precise monitoring of patient response to therapy can optimize therapy and improve patient outcomes. Find out how nanotechnology is and will continue to offer powerful solutions to these areas.

Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.

As far back as 1995, nanotechnology has offered clinicians novel tools to treat patients. Find a list of the currently approved nano-enabled therapeutics here.

Nanotechnology continues to progress into the clinic with more advanced tools than before and for more clinical indications or tumor types. Find a list of current clinical trials actively recruiting patients for these novel solutions.

Visit link:
Cancer and Nanotechnology - National Cancer Institute

The latest and updated research report on the GlobalNanobots/NanorobotsMarket covers a comprehensive overview of theNanobots/Nanorobotsmarket, future economic condition, competitive landscape mapping, supply and demand trends, and production and consumption analysis. The report also covers the influence of the COVID-19 pandemic on theNanobots/Nanorobotsmarket. The pandemic has dynamically affected all aspects of life on a global scale along with drastic changes in the economy and market conditions. The report covers the currently fluctuating market scenario along with present and future assessment of the COVID-19 impact. The report encompasses the historical data, company overview, financial standing, and necessary information about the new and key players of the market.

Magnetically guidedNanobots/Nanorobotssegment revenue is expected to register a significantly rapid rate during the forecast period. This can be attributed to increasing demand for delicate applications as magnetically guided nanorobots provide high degree of maneuverability in complex procedures.Nanobots/Nanorobotsis employed to carry and deliver live cells to targeted areas in the body, which further expected to advance, and this is expected to continue to drive revenue growth of this segment over the forecast period.

Rising investment in urgent care and increasing global geriatric population are key factors driving revenue growt of the global Nanobots/Nanorobots market

Nanobots/Nanorobots Market Size USD 6.12 Billion in 2020, Market Growth at a CAGR of 10.9%, Market Trends Advancements in technology

Get a Free sample of the report :https://www.emergenresearch.com/request-sample/744

Nanobots/Nanorobots are being used to perform complex tasks and procedures and help to reduce human error in various procedures and test in the healthcare industry. Latest studies in DNA nanotechnology support large-scale utility of nanorobots in the healthcare industry. Long-term returns derived from nanobots is encouraging market players to enter into long-term partnerships and to invest majorly in further research and development in nanotechnology. Upsurge in demand for miniaturized devices along with rapid rate of automation across various sectors are other factors fueling market revenue growth. Advancements in features ofNanobots/Nanorobotswill further drive market growth. However, increase in complexities with miniaturization is a key factor hampering revenue growth of the market currently.

Major players in the market include Bruker, Oxford Instruments, Toronto Nano Instrumentation, JEOL Ltd., Imina Technologies, Klocke Nanotechnik, Thermo-Fisher Scientific Inc., Ginkgo Bioworks, Agilent Technologies, and Park Systems.

The report offers a comprehensive overview of the competitive landscape and covers company profiles, production and manufacturing capacity, product portfolio, expansion strategies, and business initiatives such as mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches and brand promotions among others.

Nanomedicine segment accounted for largest revenue share in 2020 due to its commercialization in the healthcare industry on large scale for drug delivery, in vitro diagnostics, in vivo imaging, biomaterial, drug therapy, and active implants.

In March 2021, Bionaut Labs, which is a company that is developing nanorobots to deliver drugs for treatment of brain diseases, announced that it had received a funding of USD 20 million led by Khosla Ventures and Upfront Ventures. The funds will be used to guide Bionaut Labs through clinical and preclinical development of its nanorobot technology.

North America accounted for largest revenue share in 2020 due to high spending on healthcare and increased investment in research development of nanotechnology. Another contributing factor is increased demand forNanobots/Nanorobotsfrom the National Science Foundation (NSF) and the Defense Advanced Research Projects Agency (DARPA). Various clinical trials and pipeline projects in the U.S. for development ofNanobots/Nanorobotsin various areas are also fueling market revenue growth.

Nanobots/Nanorobotsis the technology which creates robots or machines at a very small scale. The field ofNanobots/Nanorobotsbrings together various disciplines, including nanofabrication processes used for producing nanoactuators, nanomotors, and nanosensors, among others. Rising focus on regenerative medicine coupled with technological advancements is boosting market revenue growth. Furthermore, increasing adoption of medical equipment and more advanced technologies such as Machine Learning (ML) and Artificial Intelligence (AI) is driving growth of the globalNanobots/Nanorobotsmarket, and the trend is expected to continue going ahead.

Read More:https://www.emergenresearch.com/industry-report/Nanobots/Nanorobots-market

For the purpose of this report, Emergen Research has segmented the globalNanobots/Nanorobotsmarket based on type, application, and region:

Nanomanipulator

Electron Microscope (EM)

Scanning Electron Microscope (SEM)

Transmission Electron Microscope (TEM)

Scanning Probe Microscope (SPM)

Atomic Force Microscopes (AFM)

Scanning Tunneling Microscope (STM)

Type Outlook (Revenue, USD Billion; 20182028)

Bio-Nanobots/Nanorobots

Magnetically Guided

Bacteria-Based

Application Outlook (Revenue, USD Billion; 20182028)

Nanomedicine

Biomedical

Mechanical

Others (Space and Oil Gas)

Elucidating the competitive landscape of theGlobalNanobots/NanorobotsMarket:

The globalNanobots/Nanorobotsmarket report offers viable insights into the competitive spectrum of theNanobots/Nanorobotsbusiness sphere.

The report systematically profiles the company information of each market player.

It identifies the estimated industry share, production facilities, development prospects, and geographies served by each market player.

The study showcases the extensive product portfolios of the prominent market contenders.

It offers critical data information about the product application scope and the end-user landscape.

The study provides salient information about the pricing models of the products offered by these companies. Moreover, it determines the gross profits and losses experienced by them throughout their market tenures.

Market Taxonomy:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2:

Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3:

Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4:

Regional Landscape

Chapter 5:

Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

Key geographical areas:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Request customization of the report:https://www.emergenresearch.com/request-for-customization/744

Related reports:

Patient Engagement Solutions Market:https://www.emergenresearch.com/industry-report/patient-engagement-solutions-market

Nucleic Acid Isolation and Purification Market:https://www.emergenresearch.com/industry-report/nucleic-acid-isolation-and-purification-market

Non-Invasive Prenatal Testing Market: https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market

In-Vitro Fertilization Market: https://www.emergenresearch.com/industry-report/in-vitro-fertilization-market

Blockchain in Healthcare:https://www.forbes.com/sites/forbestechcouncil/2021/12/07/four-key-medtech-software-development-trends-for-2022/?sh=23e843f420d5

About Us:At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail:[emailprotected]

Facebook|LinkdIn|Twitter|Blogs

The post Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 appeared first on Market O Graphics.

Read the original:
Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal

VICKSBURG, Miss. Researchers at the U.S. Army Engineer Research and Development Center (ERDC) are analyzing the need for increased resilience in nanotechnology supply chains.

Manufacturing and distribution of products requires a complex network of suppliers and distributors that constitute supply chains. In todays world, most people are aware of supply chains and have probably been affected by supply chain disruptions caused by the COVID-19 pandemic.

Supply chains are pivotal in the production of both military and civilian products and technologies, said Dr. Igor Linkov, senior scientific technical manager for ERDCs Environmental Laboratory (EL). Our team looked at two questions: a) how do you assess the impacts of supply chain disruptions on the manufacturing bottom line and product availability to consumers, and b) how do you mitigate supply chain disruption and increase their ability to recover, particularly when the various secondary or tertiary contributors to a supply chain are poorly characterized?

In the past, supply chains were optimized to be efficient and lean. Companies like suppliers with low labor costs and predictable and inexpensive material availabilities; suppliers having mature capabilities to ship basic or composite materials to manufacturing centers and consumers alike are also popular. However, when there is a crisis and supply chains are disrupted, efficiency may not equal the ability to recover from the disruption.

For example, it is efficient to have one supplier that covers all the material requirements for a given product, but it is not resilient because if that supplier is disrupted then the whole supply chain is impacted. On the other hand, having multiple suppliers for each component may not be efficient because of the extra costs required to maintain multiple suppliers with variable product lines, but if one supplier is disrupted, other suppliers are available, and the supply chain is less disrupted and far more capable of expeditious recovery.

The biggest thing is to understand how to balance efficiency and resilience in supply chains, Linkov said. Understanding this, organizations can work to create a more resilient supply chain for the products and services they provide.

In addition to analyzing supply chains in general, the ERDC research team also looked at supply chains as they relate to the nanotechnology industry and specifically to COVID vaccine production. Their results are published in recent paper in the journal Vaccine (https://www.sciencedirect.com/science/article/pii/S0264410X22001724?via%3Dihub), as well as in Current Opinion in Chemical Engineering (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549437/).

This research, as well as other ERDC work related to climate response and recovery, is led by Dr. Benjamin Trump, a research social scientist in ELs executive office.

Nanotechnology is an emerging technology that is the manipulation of matter on an almost atomic scale to produce new structures, materials and devices. Nanotechnology is helping to improve many technology and industry sectors, including medicine, transportation and environmental science.

One thing we looked at was the nanotechnology supply chain as it applied to vaccines, said Trump. Nano-enabled components are quickly becoming vital to vaccine production. COVID-19 vaccine candidates, for instance, used nano-enabled components to improve vaccine efficacy and delivery in vivo.

Nanotechnology allows properties of materials to be changed in a controlled way to address specific needs. In military applications, nanomaterials are used to make warfighters clothing waterproof and self-cleaning. Nanomaterials can also be used to heal wounds nanomaterials can make a shirt automatically act as an antiseptic if the warfighter is wounded.

We have tried to attract attention to the problem that in manufacturing nano-enabled products, supply chain operations are foundational logistical challenges that require careful governance, Trump said. We tried to look at how supply chain works for nano-enabled products and use this as a way to illustrate the importance of resilience and efficiency in supply chains.

Here is the original post:
ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil